EU Countries Slam Transferable Exclusivity Voucher Proposal
A group of EU member states has written to the European Commission saying that an exclusivity voucher scheme intended to stimulate R&D into new antimicrobials will stifle innovation by competitor companies and push up costs for national health systems.
You may also be interested in...
Two documents published by the European Commission outline proposals to prepare for future health emergencies such as pandemics and the impact of antimicrobial resistance, with next-generation vaccines and novel or repurposed therapeutics high on the agenda.
The European health commissioner has told members of parliament that a balance needs to be struck between promoting innovation and maximizing access to medicines across the EU member states.
If successful, a new Swedish model for reimbursing antibiotics that involves guaranteed minimum annual revenues for companies could be tested on other kinds of products.